Scribe
Pharos Scribe
AI Scientific Writing
From topic selection to submission-ready manuscript.
Explore Scribe →
Medical Devices · MDR 2017 · EU MDR · Clinical Evidence
Medical Devices Marketing Agency India.
Medical Devices Marketing Agency India.
Scientific & Commercial.
ICG's medical devices practice delivers scientific writing, HCP engagement programmes, brand communications, and commercial intelligence for medical devices brands in India. Built by IIT BHU pharmaceutical engineers who understand the therapeutic science behind the brand.
150+
Healthcare & pharma clients
1,000+
Projects delivered
9
Pharos platform modules
4×
QC layers per deliverable
0
Guideline gaps left to chance
Why medical devices requires specialist communications
Medical Devices is not
Medical Devices is not
a generic pharma category.
Medical device marketing in India operates under the Medical Devices Rules 2017 and increasingly under EU MDR-aligned standards for export markets. Device clinical evidence is structured differently from pharma clinical trials — registry data, post-market surveillance, and real-world performance data are the primary evidence base. HCP audiences are surgeons and proceduralists who make buying decisions based on technical performance, ease of use, and clinical outcomes — not pharmacological mechanism. ICG's medical devices practice covers clinical evidence communications, HCP training content, and commercial communications for device companies expanding in India and seeking international regulatory submissions.
Key service focus for medical devices
- Clinical evidence summaries for device regulatory submissions
- Surgeon training content and procedure communications
- Post-market surveillance literature support
- Device launch brand communications
Medical devices — a different evidence architecture from pharma
Medical device communications operate under an evidence architecture fundamentally different from pharma. Clinical evidence for devices is built on registry data (real-world performance across diverse user bases), post-market surveillance (CAPA-driven safety improvement), and time-and-motion clinical studies (procedural efficiency, ease-of-use, learning curve characterisation). Randomised controlled trials exist for devices but are less central than they are for pharma.
India's medical device regulatory framework
The Medical Devices Rules 2017 (MDR 2017) govern device approval in India. The Indian framework is increasingly aligned with EU MDR 2017/745 (and the upcoming EU IVDR 2017/746 for in-vitro diagnostics) — Indian device companies seeking international expansion build EU-MDR-aligned clinical evidence dossiers from Day 1. ICG's medical device engagements include EU-MDR-aligned clinical evidence summary writing as a core capability.
The surgeon and proceduralist audience
Medical device HCP audiences are surgeons, interventional cardiologists, gastroenterologists, orthopaedic surgeons, and other proceduralists. Their buying decisions are based on technical performance (device specifications, clinical outcomes), procedural ease-of-use (learning curve, ergonomics, sterilisation workflow), and clinical outcomes (patient recovery, complication rates, long-term durability). They are sceptical of marketing-led claims and respond to evidence-led communications with clear procedural utility.
ICG's medical device communications are built for this audience: technical specification accuracy, procedural workflow integration, and clinical outcome transparency. Marketing-led overclaim is the fastest path to surgeon scepticism and brand rejection.
Post-market surveillance literature support
EU MDR 2017/745 requires PMCF (Post-Market Clinical Follow-up) reports for higher-risk devices. The PMCF report integrates literature surveillance, registry data analysis, and incident report review. ICG's medical device engagements include PMCF literature support — the literature-monitoring discipline established for pharma pharmacovigilance applies equally to medical device PMCF.
Outcome targets
(1) Surgeon and proceduralist adoption — measurable via device usage data. (2) EU-MDR clinical evidence dossier acceptance — 100% on first submission. (3) PMCF report inspection-defensibility — 100% completeness against EU MDR Annex XIV requirements. (4) Brand commercial impact — measurable via territory and channel sales tracking.
Services for medical devices brands
From science
From science
to commercial impact.
🔬
Scientific Writing
Manuscripts, systematic reviews, abstracts for medical devices journals. CONSORT/PRISMA/STROBE embedded.
Explore →✍️
Medical Writing & MedComm
KOL decks, MSL materials, advisory board content for medical devices HCPs.
Explore →📈
Pharma Marketing
Brand campaigns, CLM, e-detailing, visual aids for medical devices brands.
Explore →📋
PSUR / DSUR Writing
Periodic safety reports for medical devices products. ICH E2C/E2F compliant.
Explore →🛡️
Pharmacovigilance
Literature monitoring, ICSR writing, signal detection for medical devices drugs.
Explore →
Pharos modules for medical devices
The Pharos modules most relevant
The Pharos modules most relevant
to medical devices engagements.
Scout
Pharos Scout
Literature Monitoring
Audit-ready literature surveillance for pharmacovigilance.
Explore Scout →Rxflow
Pharos RxFlow
HCP Prescription Intelligence
HCP-level prescription intelligence for relationship-driven Rx growth.
Explore RxFlow →IIT BHU Pharmaceutical Engineering
The people writing your PSUR
understand what a PSUR is.
ICG's Co-Founding Team and pharma practice lead are pharmaceutical engineers from IIT BHU's Department of Pharmaceutical Engineering and Technology — B.Tech and M.Tech graduates who have studied drug metabolism, formulation science, pharmacokinetics, and clinical pharmacology.
This is not a credential for a website. It is the reason why ICG manuscripts have fewer scientific errors in medical review, why ICG PSURs have fewer clarification cycles, and why the scoping call for a literature monitoring engagement sounds different from every other agency you've briefed. The science is understood before the brief is written.
IIT BHU
Department of Pharmaceutical Engineering & Technology
M.Pharm
Aditi Tripathi · Pharma Business Lead
B.Tech + M.Tech
Pharma Engineering · Co-Founding Team
Medical Devices.
Start with a pilot.
Pilot engagement: one medical devices deliverable — manuscript, KOL deck, PSUR section, or visual aid — full ICG process. You see how the practice works before committing.
